Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials

OBJECTIVES: To characterise the efficacy and safety of anifrolumab in patients with systemic lupus erythematosus (SLE) according to interferon gene signature (IFNGS), demographic and clinical subgroups. METHODS: We performed post hoc analyses of pooled data from the 52-week phase III TULIP-1/TULIP-2...

Descripción completa

Detalles Bibliográficos
Autores principales: Vital, Edward M, Merrill, Joan T, Morand, Eric F, Furie, Richard A, Bruce, Ian N, Tanaka, Yoshiya, Manzi, Susan, Kalunian, Kenneth C, Kalyani, Rubana N, Streicher, Katie, Abreu, Gabriel, Tummala, Raj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Systemic Lupus Erythematosus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213795/
https://www.ncbi.nlm.nih.gov/pubmed/35338035
http://dx.doi.org/10.1136/annrheumdis-2021-221425

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213795/
https://www.ncbi.nlm.nih.gov/pubmed/35338035
http://dx.doi.org/10.1136/annrheumdis-2021-221425

Ejemplares similares